[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100174756":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":7,"locations":18,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":57,"whyStopped":58,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Tomotherapy","Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT",[14],{"name":15,"affiliation":16,"role":17},"bernard GERY, MD","Centre François Baclesse","PRINCIPAL_INVESTIGATOR",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Centre François BACLESSE","Caen","14076","France","FR",{"type":26,"coordinates":27},"Point",[28,29],-0.35912,49.18585,{"lat":29,"lon":28},{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100174756","phase-2-impact-of-tomotherapy-on-xerostomia-and-quality-of-life-of-patients-with-cancer-of-the-upper-aero-digestive-tract-100174756",false,"NCT01548846","Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract","TOQUAL","Inclusion Criteria:\n\n* Patient (e) old (e) over 18 years\n* Patients with squamous cell carcinoma of head and neck (oral cavity, oropharynx, lymphadenopathy without gateway) histologically proven.\n* Patient targeted for head and neck radiotherapy by Tomotherapy exclusive with or without concurrent chemotherapy (containing platinum)\n* Indication of head and neck radiotherapy bilateral\n* All of the TNM stage except metastatic\n* Patient has signed informed consent for participation in the study\n* Mastery of the French language\n\nExclusion Criteria:\n\n* History of head and neck radiotherapy\n* Indication of head and neck radiotherapy unilateral\n* Personal history of malignant tumors uncontrolled over the past 5 years\n* History of oral sicca syndrome\n* Surgical removal of one or more salivary glands (parotid, submandibular gland, sublingual gland)\n* Concomitant treatment with amifostine\n* Concomitant treatment with cetuximab\n* Primary tumor of the salivary glands\n* Head and neck hyperfractionated radiotherapy and \u002F or accelerated\n* Head and neck radiotherapy hypofractionated\n* Metastatic disease\n* Patient deprived of liberty, under guardianship\n* Any medical condition or psychological associate that could compromise the patient's ability to participate in the study\n* Refusal of the patient.","ALL","18 Years",{"count":43,"type":44},11,"ACTUAL","INTERVENTIONAL",[47],"PHASE2","This is a study whose main objective is to evaluate prospectively the proportion of patients with severe xerostomia one year after treatment with tomotherapy for head and neck cancer.",[50,51,52],"Head and Neck Cancer","Radiotherapy by Tomotherapy Exclusive","With or Without Concurrent Chemotherapy",[54,55,56],"tomotherapy","xerostomy","head and neck squamous cell carcinoma","TERMINATED","lack of recrutment","2015-03-12",{"date":61,"type":62},"2015-03-13","ESTIMATED",{"date":64,"type":7},"2012-05",{"date":66,"type":44},"2014-12",{"name":5,"class":6},1]